Best practice guidelines for the management of women with epilepsy

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 117-124

  Crawford, Pamela ^a  

^a YORK HOSPITAL   (United Kingdom)

Author keywords

Antiepileptic drug; Contraception; Fertility; Menopause; Menstrual cycle; Polycystic ovary syndrome; Pregnancy; Reproduction

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLOMIFENE; DANAZOL; DESOGESTREL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHOSUXIMIDE; ETIRACETAM; FOLIC ACID; GESTAGEN; GOSERELIN; HORMONE; LAMOTRIGINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN K GROUP;

BREAST FEEDING; CAREGIVER; CATAMENIAL EPILEPSY; CHILD CARE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERMITTENT THERAPY; DRUG MILK LEVEL; EPILEPSY; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FRACTURE; GENETIC PREDISPOSITION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; LABOR; MENOPAUSE; MENSTRUAL CYCLE; MOTHER; OSTEOMALACIA; OSTEOPOROSIS; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK FACTOR; SEIZURE; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT; SEXUALITY; TERATOGENICITY; WOMEN'S HEALTH; ADOLESCENT; ADULT; AGE; BONE DISEASE; CHILD; CONTRACEPTION; DRUG ADMINISTRATION; GENETIC COUNSELING; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; PSYCHOSEXUAL DISORDER; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; ANTICONVULSANTS; BONE DISEASES; BREAST FEEDING; CHILD; CHILD CARE; CHILD, PRESCHOOL; CONTRACEPTION; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MENOPAUSE; MENSTRUAL CYCLE; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; SEX FACTORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 32944472740     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00323.x     Document Type: Review

References (60)

1. Crawford P, Appleton R, Betts T, et al. Guidelines for management of women with epilepsy. Seizure 1999;8:201-17.
2. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence-based medicine: what it is and what it isn't. Br Med J 1996;312:71-2.
3. Anon. The periodic health examination. Canadian Task Force on the periodic health examination. Can Med Assoc J 1979;121:193-254.
4. Betts T, Crawford P. Women and Epilepsy. London, UK: Martin Dunitz, 1998:pp.27-8.
5. Lobo RA. A disorder without identity: 'HCA', 'PCO', 'PCOD'.'PCOS', 'SLS'. What are we to call it? Fertil Steril 1995;63:1158-60.
6. Isojarvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
7. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
8. Isojarvi J, Rattya J, Knip M, et al. Replacing valproate with lamotrigine reduces cardiovascular risks and insulin mediated hyperandrogenism inwomen with epilepsy [Abstract]. Epilepsia 1997;38(suppl 3):. 279.
9. Lefevre F, Betts T. Do women who have hormonal evidence of the polycystic ovary syndrome while taking sodium valproate lose it if they switch to another anticonvulsant? Epilepsia 2004;45(suppl 7):231.
10. Bilo L, Meo R, Valentino R, et al Abnormal pattern of luteinising hormone pulsatility in women with epilepsy. Fertil Steril 1991;55:705-11.
11. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatility secretion of luteinising hormone in women with epilepsy. Neurology 1994;44:306-10.
12. Herzog AG. PCOS in women with epilepsy: epileptic or iatrogenic. Ann Neurol 1996;39:559-60.
13. Artama M, Isojarvi JI, Raitanen J, et al. Birth rate among patients with epilepsy: a nationwide population based cohort study in Finland. Am J Epidemiol 2004;159:1057-63.
14. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy. Epilepsia 1993;34:827-31.
15. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-8.
16. Backstrom T. Epileptic seizures inwomen related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976;54:321-47.
17. Neme SB, Foldvary-Schaefer NR. Lamotrigine concentrations across the menstrual cycle in women with catamenial epilepsy. Epilepsia 2004;45(suppl 7):125.
18. Rosciszewska D, Buntner B, Guz I, et al. Ovarian hormones, anticonvulsant drugs and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986;49:47-51.
19. Kumar G, Behari M, Ahuja GK, et al. Phenytoin levels in catamenial epilepsy. Epilepsia 1988;29:155-8.
20. Shavit G, Lerman P, Korczyn AD, et al. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984;34:959-61.
21. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:166-2.
22. Dana-Haeri J, Richens A. Effects of norethisterone on seizures associated with menstruation. Epilepsia 1983;24: 377-81.
23. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 1984;47:1279-82.
24. Herzog AG. Clomiphene therapy in epilepticwomen with menstrual disorders. Neurology 1988;38:432-44.
25. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-72.
26. Data on File. Research Triangle Park, NC: GlaxoSmithKline.
27. Stodieck SRG, Schwenkhagen AM. Lamotrigine plasma levels and combined monophasic oral contraceptives or a contraceptive vaginal ring, a prospective evaluation in 30 women. Epilepsia 2004;45(suppl 7):187.
28. Schwenkhagen AM, Stodieck SRG. Interaction between lamotrigine and progesten - only contraceptive pill containing desogestrel 75 μg (Cerazette). Epilepsia 2004;45(suppl 7):144.
29. Nakane Y, Okuma T, Takahishi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anticonvulsants: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-80.
30. Morrow J, Craig J. Epilepsy, pregnancy and the advent of pregnancy registers. Prog Neurol Psychiatry 2004;24-8.
31. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Australian pregnancy register of women on antiepileptic drugs: 5-year results. Epilepsia 2004;45(suppl 7):234.
32. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
33. Lindhout D, Omtzigt JGC, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(suppl 5):111-8.
34. Montouris G. Safety of the newantiepileptic drug box oxcarbazepine with during pregnancy. Cur Med Res Opin 2005;21:693-701.
35. Gaily E, Granstrom ML, Hiilesmaa V, et al. Minor abnormalities in children of mothers with epilepsy. J Pediatr 1988;112:520-9.
36. Jager-Roman E, Deichl A, Jacob S, et al. Fetal growth, major malformations, and minor anomalies in infants born towomen receiving valproic acid. J Pediatr 1986;108:997-1004.
37. Adab N, Kini U, Vinten JA, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
38. Granstrom ML, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology 1992;42(suppl 5):144-8.
39. Berkovic SR, Howell RA, Hay DA, et al. Epilepsies in twins: genetics of et al major epilepsy syndromes. Ann Neurol 1998;43:435-45.
40. Tomson T. Seizure control during pregnancy and delivery. In:Tomson T, Gram L, Sillanpaa M, et al, eds. Epilepsy and Pregnancy. Chichester, UK: Wrightson Biomedical Publishing Ltd, 1997:pp113-23.
41. Schmidt D, Ganger R, Avanzini G, et al. Change of seizure frequency in pregnant epilepticwomen. J Neurol Neurosurg Psychiatry 1983;46:751-5.
42. Licht EA, Sankar R. Status epileptic during pregnancy: a case report. J Reprod Med 1999;44:370-2.
43. Clarkson P, James A. Parenteral vitamin K: the effective prophylaxis against haemorrhagic disease for all newborn infants. N Z Med J 1990;103:95-6.
44. Sabers A. Complications during pregnancy and delivery. In:Tomson T, Gram L, Sillanpaa M, et al, eds. Epilepsy and Pregnancy. Chichester, UK: Wrightson Biomedical Publishing Ltd, 1997:pp 105-11.
45. Yerby MS. Contraception, pregnancy and lactation in women with epilepsy. Baillieres Clin Neurol 1996;5:887-908.
46. Bardy A. Epilepsy and Pregnancy, A Prospective Study of 154 Pregnancies in Epileptic Women. Helsinki, Finland: University of Helsinki, 1982.
47. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993;9:156-86.
48. Ito S, Moretti M, Liau M, Koren G. Initiation and duration of breastfeeding in women receiving antiepileptic drugs. Am J Obstet Gynecol 1995;172:881-6.
49. Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between breast differences in two patients. Eur J Pharmacol 1988;35:217-20.
50. Fleishaker JC, Desai N, McNamara PJ. Factors affecting the milk to plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharmacol Sci 1987;76:189-93.
51. Nau H, Kuhnz W, Egger HJ, et al. Anticonvulsants during pregnancy and lactation: transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982;7:508-43.
52. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004;5:102-5.
53. Ohman I, Vitols S, Thomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate during lactation. Epilepsia 2000;41:709-13.
54. Greenhill L, Betts T, Yarrow H, et al. Breast milk levels of levetiracetam after delivery. Epilepsia 2004;45(suppl 7):230.
55. Betts T, Fox C. Evaluation of a preconception clinic for women with epilepsy. Seizure 1999;8:322-7.
56. Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003;61:S16-22.
57. Abbasi F, Krumholz A, Kittner SJ, et al. Effects of menopause on seizures in women with epilepsy. Epilepsia 1999;40:205-10.
58. Crawford P, Lee P. Gender difference in the management of epilepsy What women are hearing? Seizure 1999;8:135-9.
59. Harden C, Nikolov B, Labar D, et al. Effect of hormone replacement on seizure frequency in menopausalwomen with epilepsy. Epilepsia 2004;45(suppl 7):230.
60. Elliott JO, Darby JM, Jacobson MP. Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment. Epilepsia 2004;45(suppl 7):258.